ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares are down 1.5% today after the company released fourth-quarter net earnings of $20.
In a research report sent to investors today, Oppenheimer analyst Rohit Vanjani reiterated an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $58 price …
Oppenheimer analyst Rohit Vanjani today joined the crowd, raising ANI Pharmaceuticals (NASDAQ:ANIP) price target to $55 (from $37), while maintaining an Outperform rating on the …
Roth Capital analyst Scott Henry reaffirmed a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and increased his price target to $55, following the company’s …
In a research report sent to investors Thursday, Oppenheimer analyst Rohit Vanjani assigned an Outperform rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $37 …
In a research report issued today, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) with a $40 price target, as the share …
In research note published yesterday, Roth Capital analyst Scott Henry reiterated a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 price target, …
Friday, after the close, ANI Pharmaceuticals (ANIP) announced that the company acquired US rights to the antibiotic Vancocin (125mg and 250mg capsules) from Shire (SHPG). The …
Yesterday, Roth Capital analyst Scott Henry issued a note in which he maintained a Buy rating on ANI Pharmaceuticals (ANIP) with a $40 …
In a research note released Tuesday, Roth Capital analyst Scott Henry maintained a Buy rating on ANI Pharmaceuticals (ANIP) and raised his price target to $40.00 (from $38.